www.cbsnews.com
Herasight is a genetic screening company offering prospective parents the ability to analyze embryos for DNA-based predictions of traits such as IQ, height, and potential lifespan. Priced at approximately $50,000, the service utilizes polygenic risk scoring to provide probability estimates rather than definitive outcomes. While the company markets the technology as a tool for family planning and giving children the “best start in life,” it has drawn significant ethical controversy. Critics argue that such screening commercializes human life, may lead to eugenics, and highlights socioeconomic disparities, as the high cost restricts access to the wealthy.
Read More
